We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow FLEMINGTON, N.J., May 10 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) today announced that its...
NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12 FLEMINGTON, N.J., MAY 3 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. (BULLETIN BOARD: NVDL) , a leading formulator of...
NovaDel Pharma's Third Foreign Patent Issued FLEMINGTON, N.J., April 22 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) said it was awarded Greek Patent No.GR0904055...
NovaDel CEO Interviews on Wall Street Reporter First FDA Approval Filing to Occur Within Next Two Months; Five Tier One Drugs Entering Proof of Concept Studies FLEMINGTON, N.J., April 19...
NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter FEMINGTON, N.J., April 15 /PRNewswire-FirstCall/ -- Gary Shangold, MD, chief executive officer of NovaDel Pharma, Inc. (BULLETIN...
NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting FLEMINGTON, N.J., April 14 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. (BULLETIN BOARD:...
NovaDel Reports First Quarter 2004 Progress FLEMINGTON, N.J., Apr. 7 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) reported substantial progress in product development...
NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board FLEMINGTON, N.J., March 1 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN...
NovaDel Raises $14 Million in Private Offering New Funding Will Accelerate Human Feasibility Studies of Four Top-Selling Drugs; First NDA Filing Scheduled for Q2-3 FLEMINGTON, N.J., Jan. 12...
NovaDel's Nitroglycerin Lingual Spray Achieves Important Safety and Efficacy Milestones In Randomized, Double-Blind Study FLEMINGTON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 4.92 | 6.28111834546 | 78.33 | 85.65 | 77.22 | 15888213 | 82.61204546 | SP |
4 | 13.45 | 19.2693409742 | 69.8 | 85.65 | 67.07 | 16813393 | 76.54880345 | SP |
12 | 15.81 | 23.4430604982 | 67.44 | 85.65 | 41.08 | 20474440 | 63.55892042 | SP |
26 | 43.72 | 110.59954465 | 39.53 | 91.625 | 34.28 | 21773138 | 62.44249906 | SP |
52 | 66.98150963 | 411.72541586 | 16.26849037 | 91.625 | 13.92942632 | 13927121 | 57.13681321 | SP |
156 | 78.8684199 | 1799.99950018 | 4.3815801 | 91.625 | 2.95186885 | 7394577 | 56.22591073 | SP |
260 | 78.8684199 | 1799.99950018 | 4.3815801 | 91.625 | 2.95186885 | 7394577 | 56.22591073 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions